Skip to main content
OpenTrials
Completed

NCT Number: NCT00998569

Neurocognitive Enhancement in Major Depressive Disorder

The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depressive Disorder Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Queen's University

Kingston, Ontario, K7L 3N6, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female.
  • Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.

Exclusion criteria

  • Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
  • Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
  • Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.

Treatment and study plan

Neurocognitive Enhancement

Behavioral

Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.

Wait list

Behavioral

Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.

Primary outcomes

  1. Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance

    Time frame: 20 weeks

Sponsors and collaborators

Lead sponsor

Queen's University

Other

Registry information

Acronym: MDDNET

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Oct 20, 2009
Registry last updated
Aug 31, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.